High-dose chemotherapy followed by autologous stem cell transplantation for adult patients With first relapse of Ewing's sarcoma: A single institution experience.
Humans
Adult
Female
Adolescent
Young Adult
Male
Hematopoietic Stem Cell Transplantation
Sarcoma, Ewing
/ drug therapy
Combined Modality Therapy
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Retrospective Studies
Transplantation, Autologous
Neoplasm Recurrence, Local
/ drug therapy
Neuroectodermal Tumors, Primitive, Peripheral
/ drug therapy
Chronic Disease
Sarcoma
/ drug therapy
Disease-Free Survival
Stem Cell Transplantation
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
09 Dec 2022
09 Dec 2022
Historique:
entrez:
10
1
2023
pubmed:
11
1
2023
medline:
13
1
2023
Statut:
ppublish
Résumé
The prognosis of patients with Ewing's sarcoma family of tumors (ESFT) relapse is poor; the 5-year overall survival (OS) is 13%. We evaluated the effectivity of high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) in adult patients with ESFT relapse. Between January 2010 and January 2021, we retrospectively analyzed 20 patients with ESFT who received HDT upon relapse. A combination of busulfan with melphalan was used as a conditioning regimen before ASCT. The median follow-up from diagnosis and from first relapse was 46.08 months (range; 10.71-186.87) and 14.41 months (range; 4.34-104.11), respectively. The median of age patients was 21.2 years (range, 17.6-25.3), and 10 (50%) patients were female. The tumor originated from the bone in 13 patients and soft tissue in 7 patients. Twelve patients had early (<2 years) relapse, and 8 patients had late (>2 years) relapse. Before HDT, 13 (65%) and 7 (35%) patients had pulmonary and extrapulmonary metastasis, respectively. After induction chemotherapy, 14 patients achieved complete response. The median OS1 and OS2 were 51.6 months (95% confidence interval [CI], range: 16.2-87) and 15.7 months (95% CI, range: 10.2-21.2), respectively. The 1-, 2-, and 5-year OS rates were 50%, 30%, and 15%, respectively. One patient died (sepsis) 1 month after ASCT. In univariate analyses, a disease-free interval (DFI) of < 2 years (P = .008) and incomplete response (P = .021) before ASCT were poor prognostic factors for OS2.HDT with ASCT can result in long-term survival of patients with ESFT relapse. HDT should be considered an important treatment opt ion in patients with a DFI > 2 years and complete response before transplantation.
Identifiants
pubmed: 36626465
doi: 10.1097/MD.0000000000032213
pii: 00005792-202212090-00115
pmc: PMC9750591
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e32213Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Pediatr Blood Cancer. 2011 Oct;57(4):549-53
pubmed: 21442722
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv79-iv95
pubmed: 30285218
J Clin Oncol. 2005 Jul 1;23(19):4354-62
pubmed: 15781881
Med Pediatr Oncol. 2003 Mar;40(3):141-7
pubmed: 12518341
Cancers (Basel). 2021 Mar 10;13(6):
pubmed: 33801953
Nat Rev Dis Primers. 2018 Jul 5;4(1):5
pubmed: 29977059
J Clin Oncol. 2018 Sep 6;:JCO2018782516
pubmed: 30188789
Ann Oncol. 2009 May;20 Suppl 4:140-2
pubmed: 19454436
Ann Oncol. 2006 Aug;17(8):1301-5
pubmed: 16782749
Sarcoma. 2011;2011:863210
pubmed: 21151650
Pediatr Blood Cancer. 2015 Jun;62(6):994-9
pubmed: 25585917
Sarcoma. 2018 Jun 03;2018:2640674
pubmed: 29973774
Transplant Cell Ther. 2021 Jan;27(1):72.e1-72.e7
pubmed: 33007495
Onco Targets Ther. 2019 Mar 27;12:2279-2288
pubmed: 30988632
Pediatr Blood Cancer. 2014 Aug;61(8):1382-6
pubmed: 24729428
Ann Oncol. 2003 Nov;14(11):1654-9
pubmed: 14581274
Am J Clin Oncol. 2005 Jun;28(3):301-9
pubmed: 15923805
Wien Klin Wochenschr. 2013 Mar;125(5-6):129-33
pubmed: 23440522
Pediatr Hematol Oncol. 2010 May;27(4):272-82
pubmed: 20426518